SABS News and Press, SAB Biotherapeutics Inc. From 08/08/25

SAB Biotherapeutics Inc. (SABS) is expected to report $-0.82 for Q2 2025

Recently raised $175 million in oversubscribed private placement which included strategic investor Sanofi and top-tier biotech investors Strong cash position with completed financing extending operational runway until the middle of 2028 Achieved alignment with FDA on the design an...

A look at the top 10 most actives in the United States TNF Pharmaceuticals Inc. (TNFA) rose 23.2% to $0.1078 on volume of 199,508,382 shares NuCana plc (NCNA) rose 8.0% to $0.0515 on volume of 192,535,191 shares Opendoor Technologies Inc (OPEN) rose 22.9% to $2.765 on volume of 183,615,622 ...

2025-07-21 09:27:18 ET DENVER, Colo., Jul 21, 2025 ( 247marketnews.com )- The biotech sector is buzzing with momentum as a new wave of innovation drives investor attention toward companies pushing the frontier across diverse domains; from brain health and autoimmune therapies to regener...

Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and...